Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Avacta Group (AVCT) Share Price

Price 75.50p on 28-05-2026 at 14:55:38
Change 0.50p 0.67%
Buy 77.00p
Sell 74.00p
Last Trade: Buy 32,509.00 at 76.90p
Day's Volume: 1,166,708
Last Close: 75.00p
Open: 78.00p
ISIN: GB00BYYW9G87
Day's Range 74.50p - 78.00p
52wk Range: 28.50p - 90.50p
Market Capitalisation: £343.61m
VWAP: 76.21718p
Shares in Issue: 455.11m

Avacta Group (AVCT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 32,509 76.90p Ordinary
15:55:34 - 28-May-26
Buy* 3,143 76.75p Ordinary
15:54:36 - 28-May-26
Buy* 8 76.00p SI Trade
15:52:27 - 28-May-26
Sell* 8 74.00p SI Trade
15:52:27 - 28-May-26
Buy* 20,000 76.00p Ordinary
15:52:20 - 28-May-26
Buy* 2,369 75.96p Ordinary
15:45:35 - 28-May-26
Buy* 21 75.4637p Ordinary
15:28:43 - 28-May-26
Sell* 1,000 74.00p Ordinary
15:19:23 - 28-May-26
Buy* 4 75.351p Ordinary
15:12:52 - 28-May-26
Buy* 7,755 76.00p Ordinary
15:11:28 - 28-May-26
See more Avacta Group trades

Avacta Group (AVCT) Share Price History

Time period:
to
Date Open High Low Close Volume
27th May 2026 (Wed) 78.50 75.00 75.00 75.00 976,429
26th May 2026 (Tue) 78.50 80.50 77.60 77.60 1,144,266
25th May 2026 (Mon) 79.00 79.00 79.00 79.00 0
22nd May 2026 (Fri) 78.00 79.00 75.50 79.00 1,577,106
21st May 2026 (Thu) 81.50 80.00 76.00 78.10 3,908,900
20th May 2026 (Wed) 83.50 81.00 80.00 81.00 1,763,333
19th May 2026 (Tue) 80.00 84.00 80.00 82.00 3,178,805
18th May 2026 (Mon) 86.50 85.50 84.00 84.50 1,505,495
15th May 2026 (Fri) 87.50 87.50 86.00 86.50 1,225,501
14th May 2026 (Thu) 89.00 88.00 86.90 86.90 1,283,028
13th May 2026 (Wed) 84.00 89.50 84.00 89.00 1,373,454
12th May 2026 (Tue) 90.00 90.00 83.50 85.50 3,450,117
11th May 2026 (Mon) 82.50 90.50 88.00 88.00 6,026,785
8th May 2026 (Fri) 82.00 83.00 78.00 82.50 5,285,692
7th May 2026 (Thu) 71.00 82.50 81.00 81.00 6,910,424
6th May 2026 (Wed) 78.00 76.40 71.00 71.00 2,377,307
5th May 2026 (Tue) 74.00 77.50 74.50 77.00 3,007,077
4th May 2026 (Mon) 75.00 75.00 75.00 75.00 0
1st May 2026 (Fri) 73.00 75.00 72.50 75.00 1,637,187
30th Apr 2026 (Thu) 72.00 74.00 74.00 74.00 1,211,042
29th Apr 2026 (Wed) 74.00 74.00 72.00 72.00 1,789,555
28th Apr 2026 (Tue) 75.50 74.00 73.60 73.60 1,158,888
See more Avacta Group price history

Avacta Group (AVCT) Share News

Avacta Group annual loss widens as cancer treatment trial results loom

19th May 2026 11:07

(Alliance News) - Avacta Group PLC on Tuesday said clinical data from two cancer trials is expected to be released this year as it reported a widened annual pretax loss. Read More

TRADING UPDATES: Vaalco says remainder of 2026 to be "very profitable"

21st Apr 2026 22:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued last Wednesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Somero Enterprises extends buyback to USD6.0 million

9th Apr 2026 20:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Avacta hails "important milestones" in start of "transformative" year

9th Apr 2026 13:04

(Alliance News) - Avacta Group PLC on Thursday said it "continued to build momentum" in the first quarter, highlighting favourable developments for its oncology products. Read More

IN BRIEF: Avacta raises GBP10 million in equity for clinical tests

27th Mar 2026 09:22

Avacta Group PLC - London-based biopharmaceutical company developing a tumour-activated oncology delivery platform - Raises GBP10 million from a placing of and subscription to 15.9 million new shares at 63 pence each. The new shares represent 3.6% of Avacta's total prior to the issuance. Two non-executive directors, Richard Hughes and David Bryant, contribute a total of GBP550,000 to the raise. The share offer is run by Zeus Capital as broker and bookrunner. Zeus will receive warrants over 4.4 million new shares at the same 63p price, exercisable over five years. The raise is in line with the plan announced after the London market close on Thursday. The fresh cash will be used to progress Avacta's research and development programmes into early in the first quarter of 2027, providing enough cash to get to initial data from a phase 1a trial of AVA6103, its second clinical program. AVA6103, a peptide drug conjugate. Read More

See more Avacta Group news
FTSE 100 Latest
Value10,416.82
Change-88.19

Login to your account

Forgot Password?

Not Registered